Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
LONDON - IP Group plc (LSE:IPO) announced that its portfolio company Istesso Ltd has published data demonstrating that its new class of investigational medicines can elicit tissue repair in fibrotic, autoinflammatory and autoimmune conditions.
The peer-reviewed findings, published in The Journal of Pharmacology and Experimental Therapeutics, represent what the company claims are the first oral agents to demonstrate such repair activity.
According to the press release statement, these findings could have implications for treating chronic diseases where tissue damage occurs, including rheumatoid arthritis, osteoporosis, sarcopenia, and fibrosis.
Dr. Lisa Patel, Istesso’s CEO and lead study author, described the findings as potentially redefining treatment approaches for chronic diseases. "This is the first time adaptive tissue repair has been demonstrated with oral agents in these settings," she stated.
The company also announced the appointment of Dr. Mike Owen to its Board of Directors as a non-executive director. Owen brings over 40 years of pharmaceutical and biotechnology industry experience, including his previous role as Senior Vice President and Head of Biopharmaceuticals Research at GSK from 2001 to 2009.
Owen expressed interest in Istesso’s approach to reversing tissue damage, noting its "potential to fundamentally change the treatment paradigm for chronic diseases."
IP Group currently holds a 56.5% undiluted stake in Istesso. The company indicated that additional results from Istesso’s research program will be presented at future scientific congresses and in peer-reviewed journals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.